Subscribe to RSS
DOI: 10.1055/s-2004-822970
The Contact System and Angiogenesis: Potential for Therapeutic Control of Malignancy
Publication History
Publication Date:
22 March 2004 (online)
![](https://www.thieme-connect.de/media/sth/200401/lookinside/thumbnails/10.1055-s-2004-822970-1.jpg)
We have demonstrated that domain 5 (D5, kininostatin) and cleaved high-molecular-weight kininogen (HKa) inhibit endothelial proliferation, migration, and neovascularization in the in ovo chicken chorioallantoic membrane (CAM) assay, and that D5 and HKa act by stimulating apoptosis and interfering with the cell cycle at the G1-S transition. Both intact high-molecular-weight kininogen (HK) and low-molecular-weight kininogen induce angiogenesis in the CAM assay by releasing bradykinin. A monoclonal antibody, mAb C11C1, targeted to HK D5, inhibits FGF2- (fibroblast growth factor-2) and vascular endothelial growth factor-stimulated angiogenesis in the CAM assay by interfering with the binding of HK to endothelial cells. We also demonstrate the inhibitory effects of both mAb C11C1 and glutathione-S-transferase-D5 on the growth of a human tumor supplied by CAM vessels.
KEYWORDS
Kininogen - kininostatin - urokinase receptor - prekallikrein - angiogenesis
REFERENCES
- 1 Vroman L, Adams A. Possible involvement of fibrinogen and proteolysis in surface activation: a study with the recording ellipsometer. Thromb Diath Haemorrh. 1967; 18 510-524
- 2 Schmaier A H, Silver L, Adams A L et al.. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res. 1984; 33 51-67
- 3 Brash J L, Scott C F, ten Hove P, Wojciechowski P, Colman R W. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood. 1988; 71 932-939
- 4 Scott C F, Silver L D, Purdon A D, Colman R W. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem. 1985; 260 10856-10863
- 5 Kunapuli S P, DeLa Cadena R A, Colman R W. Deletion mutagenesis of high molecular weight kininogen light chain: identification of two anionic surface binding subdomains. J Biol Chem. 1993; 268 2486-2492
- 6 DeLa Cadena R A, Colman R W. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Protein Sci. 1992; 1 151-160
- 7 Bjork I, Olson S T, Sheffer R G, Shore J D. Binding of heparin to human high molecular weight kininogen. Biochemistry. 1989; 28 1213-1221
- 8 Gustafson E J, Lukasiewicz H, Wachtfogel Y T et al.. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol. 1989; 109 377-387
- 9 Asakura S, Hurley R W, Skorstengaard K, Ohkubo I, Mosher D F. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol. 1992; 116 465-476
- 10 Yung L L, Colman R W, Cooper S L. Neutrophil adhesion on polyurethanes preadsorbed with high molecular weight kininogen. Blood. 1999; 94 2716-2724
- 11 Chavakis T, Kanse S M, Lupu F et al.. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood. 2000; 96 514-522
- 12 Chavakis T, Kanse S M, Pixley R A et al.. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J. 2001; 15 2365-2376
- 13 Shariat-Madar Z, Mahdi F, Schmaier A H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002; 277 17962-17969
- 14 Wachtfogel Y T, DeLa Cadena R A, Kunapuli S P et al.. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem. 1994; 269 19307-19312
- 15 Wei Y, Waltz D A, Rao N, Drummond R J, Rosenberg S, Chapman H A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994; 269 32380-32388
- 16 Colman R W, Pixley R A, Najamunnisa S et al.. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J Clin Invest. 1997; 100 1481-1487
- 17 Pixley R A, Sheng N, Johnson D H, Colman R W. Domain 5 of high molecular weight kininogen (HK) is responsible for the binding to the urokinase receptor [abstract]. Blood. 1999; 94 223a
- 18 Herwald H, Renne T, Meijers J CM et al.. Mapping of the discontinuous kininogen binding site of prekallikrein: a distal binding segment is located in the heavy chain domain A4. J Biol Chem. 1996; 271 13061-13067
- 19 Hasan A AK, Zisman T, Schmaier A H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA. 1998; 95 3615-3620
- 20 Mahdi F, Shariat-Madar Z, Todd III R F, Figueroa C D, Schmaier A H. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood. 2001; 97 2342-2350
- 21 Tait J F, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem. 1987; 262 11651-11656
- 22 Lin Y, Harris R B, Yan W, McCrae K R, Zhang H, Colman R W. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood. 1997; 90 690-697
- 23 Colman R W, Jameson B A, Lin Y, Johnson D, Mousa S A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000; 95 543-550
- 24 Lin Y, Pixley R A, Colman R W. Kinetic analysis of the role of zinc in the interaction of domain 5 of high-molecular-weight kininogen (HK) with heparin. Biochemistry. 2000; 39 5104-5110
- 25 Guo Y L, Wang S, Colman R W. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001; 21 1427-1433
- 26 Sun H, Tonks N K, Bar-Sagi D. Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science. 1994; 266 285-288
- 27 Guan Z, Buckman S Y, Miller B W, Springer L D, Morrison A R. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem. 1998; 273 28670-28676
- 28 Guo Y L, Baysal K, Kang B, Yang L J, Williamson J R. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem. 1998; 273 4027-4034
- 29 Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, Gulbins E. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem. 1997; 272 22173-22181
- 30 King K L, Cidlowski J A. Cell cycle regulation and apoptosis. Annu Rev Physiol. 1998; 60 601-617
- 31 Colman R W, Pixley R A, Sainz I et al.. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost. 2003; 1 164-170
- 32 Song J S, Sainz I M, Cosenza S C, Reddy E P, Colman R W. Inhibition of tumor angiogenesis in vivo by monoclonal antibody targeted to domain 5 of high molecular weight kininogen [abstract]. Thromb Haemost (suppl). 2001; , Abstract OC1674
- 33 Parenti A, Morbidelli L, Ledda F, Granger H J, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001; 15 1487-1489
- 34 Maier M, Austen K F, Spragg J. Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens. Proc Natl Acad Sci USA. 1983; 80 3928-3932
- 35 Kimura M, Sueyoshi T, Takada K, Tanaka K, Morita T, Iwanaga S. Isolation and characterization of ornitho-kininogen. Eur J Biochem. 1987; 168 493-501
- 36 Scott C F, Silver L D, Schapira M, Colman R W. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest. 1984; 73 954-962
- 37 Colman R W, Schmaier A H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997; 90 3819-3843
- 38 Chavakis T, Pixley R A, Isordia-Salas I, Colman R W, Preissner K T. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J Biol Chem. 2002; 277 32677-32682
- 39 Ferrara N. Vascular endothelial growth factor. In: Claesson-Welsh L Molecular and Biological Aspects in Vascular Growth Factors. Berlin; Springer 1999: 37-45
- 40 Sainz I, Long W K, Colman R W. Effect of monoclonal antibodies to high molecular weight kininogen (HK) on growth and neovascularization of murine syngenetic tumors [abstract]. Thromb Haemost. 2001; , (suppl) Abstract #OC1675
- 41 Schmaier A H, Wahl R, Fisher S J, Brenner D. The pharmacokinetics of the kininogens. Thromb Res. 1998; 92 293-297
- 42 Wang S, Hasham M G, Isordia-Salas I, Tsygankov A Y, Colman R W, Guo Y L. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high molecular weight kininogen. Heart Circ Physiol. 2003; 284 H1917-1923
- 43 Zhang J C, Claffey K, Sakthivel R et al.. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. 2000; 14 2589-2600
- 44 Colman R W. Biologic activities of the contact factors in vivo: potentiation of hypotension; inflammation; and fibrinolysis; and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb Haemost. 1999; 82 1568-1577
- 45 Colman R W, Jameson B A, Lin Y, Johnson D, Mousa S A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000; 95 543-550
- 46 Guo Y L, Wang S, Colman R W. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001; 21 1427-1433
Robert W ColmanM.D.
The Sol Sherry Thrombosis Research Center, Temple University School of Medicine
3400 North Broad Street, Room 300 OMS
Philadelphia, PA 19140
Email: colmanr@astro.temple.edu